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Development of malignant edema (ME) is a life-threat-ening complication and typically occurs in younger 
patients with a large middle cerebral artery (MCA) infarc-
tion.1 Such a malignant MCA infarction occurs in ≤10% of the 
patients with large supratentorial stroke.2 No official definition 
exists for ME, but stroke researchers often use the combina-
tion of clinical deterioration and midline shift on computed 
tomography (CT) imaging, although some only use the im-
aging definition.3,4 Usually, the edema develops between the 
second and fifth day after the stroke, although onset of symp-
toms before 24 hours after the stroke is not uncommon. Before 
surgical intervention was introduced, reported mortality rates 
associated with malignant MCA infarction ranged between 
70% and 80%.1,5 In a pooled analysis of 3 randomized trials, 
early decompressive surgery has been shown to be effective in 
patients with malignant MCA infarction in terms of improving 
clinical outcome and reducing mortality rate.6 Anticipating on 
development of ME is important, so that the patient can be 
treated on time. Therefore, prediction of ME is helpful.
Single predictors of malignant MCA infarction have 
been investigated previously and include both clinical and 
imaging factors. Clinical features that are present on ad-
mission have been related to ME and include age, vomit-
ing, National Institutes of Health Stroke Scale (NIHSS), and 
coma.7–11 However, the predictive value of clinical parameters 
regarding malignant MCA infarction is limited, and, there-
fore, imaging factors are an important addition to prediction 
models. Imaging factors that have been associated with ME 
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independently of age and NIHSS include early signs of is-
chemia on noncontrast CT (NCCT), larger volume of deficits 
on cerebral blood volume maps, higher blood-brain perme-
ability estimates on CT perfusion (CTP), more proximal 
thrombus location, higher clot burden score, and poor collat-
eral scores on CT angiography (CTA).10–13 Similarly, larger 
size of the MCA infarction on diffusion-weighted imaging has 
been found to be associated with ME.8,14
Another potential predictor of ME may be the volume 
of intracranial cerebrospinal fluid (CSF) on admission. 
Theoretically, the brain has more space to swell, without her-
niating, when more CSF volume is present. To assess the pre-
dictive value of CSF volume in relation to ME, we evaluated 
a large prospective cohort of patients with MCA infarction.
Methods
Descriptive data that support the findings of this study are available 
from the corresponding author on reasonable request.
Patient Selection
Patients were selected from a prospective multicenter observa-
tional cohort study, the DUST (Dutch Acute Stroke Study), be-
tween May 2009 and August 2013.15 Patients, who participated 
in DUST, were adult (≥18 years), had suspected ischemic stroke 
based on clinical signs, presentation within 9 hours after onset 
of neurological deficits, and NIHSS ≥2, or 1 if an indication for 
intravenous administration of tPA (tissue-type plasminogen acti-
vator) was present.15 Exclusion criteria were contraindications for 
undergoing CT at admission including contrast allergy and renal 
failure or the presence of other causes for the neurological deficits 
on brain CT. Patient characteristics were collected, and all patients 
underwent CT imaging including NCCT, CTP, and CTA on hos-
pital admission. This study was approved by the medical ethics 
committees of the participating hospitals. Signed informed con-
sent was taken from all participants or their families. In case the 
patient died, the need for informed consent was waived by the 
medical ethics committee.
For the current study, we selected patients from DUST who had 
an occlusion proximal to the M3 segment of the MCA. Furthermore, 
patients were excluded if thin-slice NCCT at baseline was unavail-
able. Because we were only interested in midline shift caused by ME 
as outcome, patients were excluded if hemorrhagic transformation 
causing mass effect was present on follow-up CT.
Baseline Data
The following patient characteristics were collected at baseline: age, 
sex, NIHSS, time from symptom onset to CT scan, intravenous ad-
ministration of tPA, endovascular treatment, cardiovascular risk fac-
tors, and previous medical history of cardiovascular disease.
Imaging Protocol
The imaging protocols have been described previously.15 In short, 
NCCT, CTP, and CTA scans were acquired as part of the acute stroke 
protocol. Follow-up NCCTs were planned on the third day after the 
stroke or at the moment of clinical deterioration. CT scanners (Philips, 
Siemens, Toshiba, and General Electric Company) with varying colli-
mation widths, ranging from 40 to 320 slices, were used in this study. 
The tube settings for the NCCT were 120 kVp and 300 to 375 mAs 
per rotation. Slices were reconstructed with a thickness of 1 mm.
CTP was performed with 80 kVp and 150 mAs with a slice thick-
ness of 5 mm. In dynamic mode, successive image frames were 
acquired (every 2 seconds for the duration of 50 seconds), while non-
ionic contrast material and saline were administered.15 Both Alberta 
Stroke Program Early CT Score levels were included in the CTP 
coverage.16
CTA covered the head and neck from aortic arch to cranial 
vertex. The scan delay after intravenous injection of contrast was 
calculated from time to peak arterial enhancement on CTP or by 
trigger-based Hounsfield unit threshold measurement of contrast 
enhancement in the aortic arch.
Imaging Analysis
Imaging data were evaluated by 1 of 3 observers, who all have >5 
years of experience in stroke imaging.17 The observers were only in-
formed about the side of symptoms before evaluation.
Baseline NCCT scans were evaluated for presence of hyperdense 
vessel sign and early signs of ischemia, which were quantified by 
using the Alberta Stroke Program Early CT Score.16
Fully automated intracranial CSF volume estimation was based 
on gray value histograms of the NCCT brain parenchyma. To this 
end, first, the brain was coarsely segmented into 3 tissue regions 
(gray matter, white matter, and CSF) by registering the International 
Consortium for Brain Mapping 152 nonlinear atlas18,19 to the NCCT 
scan using penalized elastic deformation.20 Aided by this segmen-
tation, 3 gaussian mixture models were fitted to the histograms of 
coarsely segmented tissue regions (Figure 1). The use of a mixture 
model allows for volume measurement in noisy data, without the 
need for precise segmentation. The area under each gaussian curve 
reflects the volume of the particular tissue region.
The intracranial volume (ICV) was defined as the sum of the gray 
matter, white matter, and CSF atlas regions, that is, the sum of the 
areas under the 3 histograms. The intracranial CSF volume was de-
fined as the sum of the areas under the curve of the CSF distributions 
of the gaussian mixtures inside those masks.
ME was defined as a midline shift of >5 mm. Types of hem-
orrhagic transformation including hemorrhagic transformation 
with mass effect (type PH-2) were evaluated by using the ECASS 
(European Cooperative Acute Stroke Study) criteria.21
For CTP, Alberta Stroke Program Early CT Score was evaluated 
on perfusion maps, which included cerebral blood volume and mean 
transit time and were calculated by using commercially available CTP 
software (Extended Brilliance Workstation 4.5; Philips Healthcare).
On baseline CTA, intracranial artery occlusions and collateral 
status were evaluated.22–24 The most proximal occlusion was used 
if multiple occlusions were present, with the exception of a tandem 
lesion of the extracranial internal carotid artery (ICA) and MCA, in 
which case the MCA occlusion was used.25 The collateral score was 
categorized as either poor or good (cutoff, 50%) compared with the 
contralateral hemisphere by visual inspection of the maximum-inten-
sity projection images.17
Outcome Measures
Primary outcome was the presence of ME on follow-up imaging. 
The secondary outcome measure was clinical outcome after 90 
days. Poor clinical outcome was defined as a score of ≥3 on the 
modified Rankin Scale.
Statistical Analysis
Patient characteristics and outcomes were compared between the 
patients included for this study and the patients who were excluded 
because of unavailability of thin-slice NCCT images by using 
variable-dependent statistical tests (Table I in the online-only Data 
Supplement). Similarly, patient characteristics were compared be-
tween patients with and without malignant MCA infarction. The in-
tracranial CSF volume was adjusted for ICV by calculating the ratio 
of CSF volume to ICV (CSF/ICV). Odds ratios (ORs) and 95% CIs 
were calculated by using binary logistic regression. Potential predic-
tors were identified by screening the literature. Complete-case anal-
ysis was performed because no missing values were present for the 
predictors of interest. Because of the limited number of outcomes, we 
could only select 3 potential predictors per model. Because younger 
patients have a higher risk of developing ME than older patients, 
we added age to one of the models. Similarly, we added NIHSS to 
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terminal ICA or M1 occlusion and poor collateral score. Subgroup 
analyses were done for the patient group aged from 18 to 60 and for 
the group with NIHSS of ≥16. Variance inflation factors were cal-
culated to test the collinearity assumption, which was not violated. 
Receiver operating characteristic curves were plotted from the pre-
dicted probabilities. The areas under the receiver operating charac-
teristic curves (AUROC), were calculated and model performances 
were compared by using the likelihood ratio test, so that the added 
value of CSF/ICV could be calculated. The described analyses were 
performed in R (version 3.4.2).
Results
We selected 472 patients with an MCA occlusion prox-
imal to the M3 segment (Figure I in the online-only Data 
Supplement). We excluded 179 cases because no thin-slice 
NCCT was available at baseline. At follow-up, 7 patients had 
hemorrhagic transformation with mass effect (PH-2) and were 
thus excluded. The final analysis included 286 patients, of 
whom 35 (12%) developed ME. No more than 10 (3%) miss-
ing values were present for the patient characteristics except 
for smoking (n=24; 8%). Twenty-two (33%) of the 69 patients 
with terminal ICA or proximal M1 occlusion developed ME. 
Twelve (6%) of the 217 patients with an occlusion distal to the 
terminal ICA or proximal M1 segment developed ME.
The patients without baseline thin-slice NCCT and 
without PH-2 during follow-up are compared with the in-
cluded patients (Table I in the online-only Data Supplement). 
In the group that was excluded because of unavailability of 
thin-slice NCCT images, 19 of 175 (11%) patients developed 
malignant MCA infarction. This number was not significantly 
different from the included group (P=0.766).
Patient characteristics of the selected study population 
are summarized in Table 1. Crude ORs are shown in Table 
II in the online-only Data Supplement. Age was significantly 
lower in the ME group than in the non-ME group (OR, 1.5; 
95% CI, 1.2–2.0) as was increase in admission NIHSS (OR, 
1.2; 95% CI, 1.1–1.3). No large differences were observed 
between the 2 groups regarding treatment or cardiovascular 
risk factors. Specific imaging findings on admission that were 
more prevalent in the ME group than in the non-ME group 
included hyperdense vessel sign (OR, 3.5; 95% CI, 1.7–8.0), 
lower Alberta Stroke Program Early CT Score (OR, 1.8; 95% 
CI, 1.5–2.1), terminal ICA, or proximal M1 occlusion (OR, 
7.3; 95% CI, 3.5–16.0) and poor collateral score (OR, 7.3; 
95% CI, 3.4–16.7). Decrease in CSF/ICV was significantly 
associated with malignant MCA infarction (OR, 4.5; 95% CI, 
1.9–11.7). Examples illustrating the association between CSF/
ICV and ME are shown in Figure 2. Prevalence of poor clin-
ical outcome 90 days after the stroke was higher in the ME 
group than in the non-ME group (97% versus 47%, respec-
tively; P<0.001).
The results of the multivariable analysis are shown in 
Table 2 and details of the receiver operating characteristic 
curves in Table 3 and Figure 3. In model 1, CSF/ICV was as-
sociated with ME independent of age and admission NIHSS 
(OR, 3.3; 95% CI, 1.1–11.3). The model with CSF/ICV had a 
significantly better performance than the model without CSF/
ICV when comparing the AUROCs (0.824 versus 0.795, re-
spectively; P=0.033). In model 2, CSF/ICV was associated 
with ME independent of admission NIHSS and poor collat-
eral score (OR, 7.0; 95% CI, 2.6–21.3). A significant differ-
ence was observed between the performance of the model 
with CSF/ICV and the model without CSF/ICV (AUROC, 
0.850 versus 0.813, respectively; P<0.001). In model 3, CSF/
ICV was associated with ME independent of the presence of 
a terminal ICA or proximal M1 occlusion and poor collateral 
score (OR, 7.7; 95% CI, 2.8–23.9). Furthermore, a significant 
difference was found between the performance of model 3 
with CSF/ICV and without CSF/ICV (AUROC, 0.856 versus 
0.811, respectively; P<0.001).
Of the 87 patients aged from 18 to 60, 20 (23%) developed 
ME (Table III in the online-only Data Supplement). In this 
group of patients, no significant associations between CSF/
ICV and ME were observed in the 3 multivariable models 
(Table IV in the online-only Data Supplement). The 3 models 
did not improve significantly after CSF/ICV was added (Table 
V in the online-only Data Supplement).
Of the 95 patients with an NIHSS of ≥16, 21 (22%) devel-
oped ME (Table VI in the online-only Data Supplement). In 
this group of patients, no associations between CSF/ICV and 
ME were observed in the 3 multivariable models (Table VII 
in the online-only Data Supplement). Only model 2 improved 
Figure 1. Gaussian mixture models fitted to noncontrast computed tomography (CT) histograms. An example of gaussian mixture models fitted to 3 noncon-
trast CT histograms: coarsely segmented gray matter, white matter, and cerebrospinal fluid (CSF). The solid line represents the measured intensity histogram, 
whereas the dashed line represents the mixture model. The mixture model consists of 3 gaussian distributions: gray matter (light gray; mean, 33.6 HU), white 
matter (dark gray; mean, 27.0 HU), and CSF (black; mean, 9.5 HU). Note that the gray matter histogram is dominated by the gray matter peak, the white mat-
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significantly (P=0.047) after CSF/ICV was added (Table VIII 
in the online-only Data Supplement).
Discussion
In this study, we evaluated the added value of the ratio of 
intracranial CSF volume to ICV in predicting ME. By build-
ing 3 statistical models, we showed that CSF/ICV is a pre-
dictor of malignant MCA infarction independent of (1) age 
and NIHSS, (2) NIHSS and poor collateral score, and (3) 
terminal ICA or proximal M1 occlusion and poor collateral 
score. When comparing performances of the models with and 
without CSF/ICV, the 3 models improved significantly after 
CSF/ICV was added.
Our results are in accordance with the only previous 
study that investigated the association between intracranial 
CSF volume and ME.26 In the previous study, which had a 
retrospective design, half of the 52 patients with terminal 
carotid or proximal M1 occlusion developed ME, whereas 
Table 1. Patient Characteristics
Characteristics
Total (n=286) ME (n=35) No ME (n=251)
P Value* 12% 88%
Age, y; mean±SD 67±14 59±16 68±14 0.003
Male sex, n (%) 162 (57) 23 (66) 139 (55) 0.248
Admission NIHSS, median (Q1–Q3) 13 (7–17) 18 (14–20) 12 (7–16) <0.001
Time from symptom onset to scan, min; 
median (Q1–Q3)
113 (68–160) 135 (81–231) 104 (67–157) 0.187
Intravenous tPA, n (%) 201 (70) 21 (60) 180 (72) 0.155
Endovascular treatment, n (%) 33 (12) 6 (17) 27 (11) 0.268
Medical history
  Hypertension, n (%) 145 (51) 17 (49) 128 (51) 0.753
  Diabetes mellitus, n (%) 36 (13) 2 (6) 34 (14) 0.191
  Hyperlipidemia, n (%) 80 (28) 8 (23) 72 (29) 0.440
  Smoking currently, n (%) 79 (30) 8 (29) 71 (30) 0.847
  Former smoking, n (%) 83 (32) 8 (29) 75 (32) 0.708
  Never smoked, n (%) 100 (38) 12 (43) 88 (38) 0.589
  Atrial fibrillation, n (%) 47 (17) 6 (17) 41 (17) 0.936
  Stroke/TIA, n (%) 56 (20) 7 (21) 49 (20) 0.883
  MI, n (%) 41 (15) 6 (17) 35 (14) 0.641
Imaging findings
  Hyperdense vessel sign, n (%) 126 (44) 24 (71) 102 (41) <0.001
  NCCT ASPECTS, median (Q1–Q3) 10 (8–10) 7 (3–8) 10 (8–10) <0.001
  CSF volume, mL; mean±SD 171±65 137±57 175±65 <0.001
  ICV volume, mL; mean±SD 1322±155 1307±161 1324±154 0.556
  CSF/ICV percentage, mean±SD 13±5 11±4 13±5 <0.001
  CBV ASPECTS, median (Q1–Q3) 7 (5–9) 3 (1–5) 8 (6–10) <0.001
  MTT ASPECTS, median (Q1–Q3) 3 (2–6) 0 (0–2) 4 (2–6) <0.001
  Terminal ICA/proximal M1 occlusion, n (%) 69 (24) 22 (63) 47 (19) <0.001
  Poor collateral score, n (%) 89 (31) 25 (71) 64 (25) <0.001
Follow-up
  Time between admission and follow-up CT, 
d; median (Q1–Q3)
3.0 (2.0–4.0) 2.2 (1.4–3.9) 3.0 (2.1–4.0) 0.063
  Poor clinical outcome at 90 d,† n (%) 151 (53) 34 (97) 117 (47) <0.001
ASPECTS indicates Alberta Stroke Program Early CT Score; CBV, cerebral blood volume; CSF, cerebrospinal fluid; CT, computed tomography; 
ICA, internal carotid artery; ICV, intracranial volume; ME, malignant edema; MI, myocardial infarction; mRS, modified Rankin Scale; MTT, mean 
transit time; NCCT, noncontrast computed tomography; NIHSS, National Institutes of Health Stroke Scale; TIA, transient ischemic attack; and 
tPA, tissue-type plasminogen activator.
*Either parametric or nonparametric tests were performed depending on the variable distribution.
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in our study, 12% developed ME. This difference can be 
explained by the different use of selection criteria. In the 
previous study, patients with an ICA or proximal M1 occlu-
sion were included, whereas in our study, we also included 
patients with a distal M1 or M2 occlusion. In our study, 33% 
(22 of 69) of the patients with terminal ICA or proximal M1 
occlusion developed ME. As expected, the presence of a ter-
minal ICA or proximal M1 occlusion was associated with 
the development of ME as compared with the presence of a 
more distal occlusion. Nonetheless, 6% of the patients with 
an occlusion of the distal M1 segment or M2 segment of the 
MCA also developed ME. This implies that future studies 
should not only address the most proximal MCA occlusions, 
although these patients face the highest risk of developing 
malignant MCA infarction.
As brain volume shrinks with increasing age, it is not sur-
prising that patients who develop ME are typically younger 
than patients who do not develop ME because there is less 
space for the brain to swell without causing herniation.1 Similar 
to atrophy, previous stroke, which is typically a disease of the 
elderly, may lead to an increase of the ratio of intracranial CSF 
volume to ICV. In our study, patients with malignant MCA in-
farction were indeed younger than the patients without malig-
nant MCA infarction. We did not formally test the correlation 
between age and CSF/ICV, but the assumption of collinearity 
between predictors was not violated. Moreover, when adjusted 
for age and admission NIHSS, CSF/ICV was still significantly 
related to ME, and the clinical model improved significantly 
after CSF/ICV was added. The observed associations did not 
hold in the subgroup analyses of patients aged from 18 to 60 
and patients with an NIHSS of ≥16. Although the ORs indi-
cated a positive association between CSF/ICV and malignant 
MCA infarction for these subgroups, the power was too low 
for the associations to reach significance.
Similarly to the clinical model, CSF/ICV was of added 
value to the imaging prediction model. In fact, the AUROC 
of the imaging model was even higher than the AUROC of 
the clinical model. However, we did not formally test the dif-
ference between the performances of the clinical and imaging 
models because this was not our primary research question. 
Still, these results emphasize the need for the use of imaging 
findings for the prediction of malignant MCA infarction and, 
perhaps, other complications of stroke.
One strength of this study was the prospective design. As a 
consequence, we only had few missing data and a low number 
of dropouts, which minimizes the risks of information bias 
and selection bias, respectively. Another strong point of this 
study was the quantification of the intracranial CSF volume 
and ICV by applying a brain atlas on the CT scans. Because 
this is an entirely automated technique for quantifying brain 
volumes, neither observation bias nor interrater reliability is 
an issue for this measurement of interest. Furthermore, this 
method is robust to CT noise, loss of gray-white differentia-
tion, or other early ischemic changes on NCCT as the volumes 
are derived from mixture model histograms and not directly 
from segmentations.
One of the limitations of this study was the large number 
of exclusions because of the unavailability of thin-slice NCCT 
images, which was not a standard procedure for the DUST 
study. We chose to exclude those patients because volume 
measurements would be less precise on thick-slice images and 
for the sake of the uniformity of the measurements. However, 
we do not think that excluding patients in this manner influ-
ences the results because the collection of thin-slice data is a 
Figure 2. Examples illustrating the association between the ratio of intra-
cranial cerebrospinal fluid volume (CSF) and intracranial volume (ICV) and 
malignant middle cerebral artery (MCA) infarction. First example of a base-
line noncontrast computed tomography (CT) image of an 81-y-old man with 
a large MCA infarction due to an occlusion of the proximal M1 segment (A). 
The ratio between intracranial CSF/ICV was 0.19. On follow-up, noncontrast 
CT demarcation of the infarction is visible, but no midline shift has occurred 
(B). Second example of a baseline noncontrast CT image of a 52-y-old 
woman with a large MCA infarction due to an occlusion of the proximal M1 
segment (C). The CSF/ICV was 0.08. On follow-up, noncontrast CT malig-
nant edema has developed leading to a midline shift of >5 mm (D).
Table 2. Multivariable Prediction Models and the Association With Malignant Middle Cerebral Artery Infarction
Factor Model 1, OR (95% CI) Model 2, OR (95% CI) Model 3, OR (95% CI)
Age, per 10 y decrease 1.4 (1.0–1.9)   
Admission NIHSS, per point increase 1.2 (1.1–1.3) 1.2 (1.1–1.3)  
Terminal ICA/proximal M1 occlusion   7.8 (3.4–19.3)
Poor collateral score  5.5 (2.4–13.6) 8.2 (3.5–21.0)
CSF/ICV, per 10% decrease 3.3 (1.1–11.1) 7.0 (2.6–21.3) 7.7 (2.8–23.9)
CSF indicates cerebrospinal fluid; ICA, internal carotid artery; ICV, intracranial volume; NIHSS, National Institutes of Health Stroke 
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random feature and neither related to CSF volume nor the de-
velopment of ME. Furthermore, no large relevant differences 
were observed between the characteristics of the included and 
excluded patient groups. In general, thin-slice NCCT data 
are nowadays routinely acquired as part of stroke imaging 
protocols. Another drawback of this study was the limited 
number of outcomes. As a consequence, we could not add 
>3 variables to the prediction models, and we were not able 
to include CTP variables or build a large prognostic model. 
Unfortunately, we did not have a sufficient large sample size 
either for developing a new clinically usable prediction model 
or for validating a previously developed model.10 In the fu-
ture, larger cohorts with MCA infarction should be evaluated 
for the purpose of developing a prediction model that can 
be readily used in clinical practice. We used a dichotomized 
measure of midline shift as the primary outcome. Although 
dichotomizing this measure may lead to loss of information, 
we think that interrater variability is lower than when a con-
tinuous measure was used, but we were not able to formally 
test this assumption.
We did not use clinical information to define malignant 
MCA infarctions. Although some previous studies used both 
clinical and imaging information for defining ME, we think 
that solely using the quantitative measure of midline shift is 
sufficient to identify malignant MCA infarction as has been 
done previously.4 We did not collect data on treatment of ma-
lignant MCA infarction. As a result, we were not able to eval-
uate whether patients, who have been treated, would have been 
treated sooner, or patients, who have not been treated, would 
have been treated after taking into account the results of this 
study. Still, we found that CSF/ICV significantly improves 3 
types of prediction models. As a consequence, patients at risk 
for malignant MCA infarction can be recognized and treated 
earlier. In the future, larger prediction models need to be de-
veloped, and their influence on patient management and clin-
ical outcome should be evaluated.
In conclusion, the CSF/ICV ratio is associated with ma-
lignant MCA infarction and has added value to clinical and 
imaging prediction models in limited numbers of patients.
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Figure 3. Performance of prediction models with and without the ratio between intracranial cerebrospinal fluid volume (CSF) and intracranial volume (ICV). 
Clinical prediction model (A), prediction model with clinical and imaging predictors (B), and imaging prediction model (C) with and without the ratio between 
intracranial CSF/ICV, respectively. Proximal occlusion indicates terminal internal carotid artery or proximal M1 occlusion. NIHSS indicates National Institutes 
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